[go: up one dir, main page]

WO2008136754A1 - Nouveaux dérivés de benzyl-2-oxo-pipérazinyl/7-oxo/5-oxa-[1,4]-diazépanyl/2-oxo- tétrahydropyrimidinyle - Google Patents

Nouveaux dérivés de benzyl-2-oxo-pipérazinyl/7-oxo/5-oxa-[1,4]-diazépanyl/2-oxo- tétrahydropyrimidinyle Download PDF

Info

Publication number
WO2008136754A1
WO2008136754A1 PCT/SE2008/050520 SE2008050520W WO2008136754A1 WO 2008136754 A1 WO2008136754 A1 WO 2008136754A1 SE 2008050520 W SE2008050520 W SE 2008050520W WO 2008136754 A1 WO2008136754 A1 WO 2008136754A1
Authority
WO
WIPO (PCT)
Prior art keywords
chlorobenzyl
acetamide
halogen
hydrogen
compound
Prior art date
Application number
PCT/SE2008/050520
Other languages
English (en)
Inventor
Laurent David
Nafizal Hossain
Marguerite Mensonides-Harsema
Tesfaledet Mussie
Åsa SJÖHOLM Timèn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of WO2008136754A1 publication Critical patent/WO2008136754A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/34—Ethylene-urea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings

Definitions

  • the present invention relates to new compounds, to pharmaceutical composition containing said compounds and to the use of said compounds in therapy.
  • the present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof.
  • Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma, chronic obstructive pulmonary disease (COPD), allergic diseases, rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.
  • Chemokines are attractants and activators of monocytes, lymphocytes and neutrophils.
  • the C-C chemokines include potent chemoattractants such as human monocyte chemotactic proteins 1-3 (MCP-I, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins l ⁇ and l ⁇ (MIP-l ⁇ and MIP- l ⁇ ).
  • the C-X-C chemokines include several potent chemoattractants such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).
  • CCRl G protein-coupled receptors
  • CCR2A the receptors designated CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO, CXCRl, CXCR2, CXCR3 and CXCR4.
  • Chemokine Receptor 1 CCRl is highly expressed in tissues affected in different autoimmune, inflammatory, proliferative, hyper proliferative and immunologically mediated diseases, e.g. asthma, chronic obstructive pulmonary disease, multiple sclerosis and rheumatoid arthritis. Therefore, inhibiting CCRl -mediated events is expected to be effective in the treatment of such conditions.
  • a desirable property for a drug acting at the CCRl receptor is that it has high potency e.g. as determined by its ability to inhibit the activity of the CCRl receptor. It is also desirable for such drugs to possess good selectivity and pharmacokinetic properties in order to further enhance drug efficacy. As an example, it can be advantageous for such drugs to possess good metabolic stability and bioavailability.
  • hERG human ether-a-go-go- related-gene
  • the present inventors have identified new compounds which modulate CCRl receptor activity and which are contemplated to have a particularly beneficial potency, selectivity and/or pharmacokinetic properties.
  • n 0, 1 or 2;
  • R 1 is halogen or Ci-C 6 haloalkyl
  • Q is -CH 2 - or -C(O)- ;
  • X, Y and Z are a bond, -CH 2 - or -C(O)-, provided that X, Y and Z are not all the same and that at least one of X, Y or Z is -C(O)-; q is 1 or 2;
  • R 2 is hydrogen or C 1 -C 4 alkyl
  • A is a bond, -0-, or C1-C3 alkyl
  • R 3 is hydrogen, -NHC(O)R 6 , -NHS(O) 2 R 6 , -C(O)NR 7 R 8 , -COOR 9 , SO 3 R 9 or Ci-C 6 alkyl optionally substituted by t substituents independently selected from halogen, cyano, amino or hydroxyl; t is O, 1, 2 or 3;
  • R 4 is hydrogen, halogen, hydroxyl, C 1 -C 3 alkoxy or Ci-C 6 hydroxyalkyl optionally substituted by u substituents independently selected from halogen, cyano, amino, CONH 2 , hydroxyl, Ci-C 6 haloalkyl, carboxyl, Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonyl Or Ci-C 6 alkylcarbonylamino; u is O, 1, 2 or 3; p is O, 1, 2 or 3;
  • R 5 is halogen, cyano, C 1 -C 3 alkoxy or Ci-C 3 haloalkyl
  • R 6 is (i) hydrogen; (ii) Ci-C 6 alkyl; (iii) a 3- to 6-membered saturated or unsaturated ring, optionally comprising one or more heteroatom selected from nitrogen, oxygen and sulphur, and optionally further comprising a bridging group, the ring being optionally substituted with one or more substituent independently selected from halogen, hydroxyl, Ci-C 6 alkyl, Ci-C 6 hydroxyalkyl and Ci-C 6 haloalkyl, -O- and -OR 9 ; (iv) NR 7 R 8 ;
  • R 7 and R 8 each independently represent; (i) hydrogen
  • a 3- to 6-membered saturated or unsaturated ring optionally comprising one or more heteroatom selected from nitrogen, oxygen and sulphur, and optionally further comprising a bridging group, the ring being optionally substituted with one or more substituent independently selected from halogen, hydroxyl, -0-, Ci-C 6 alkyl, Ci-C 6 hydroxyalkyl and Ci-C 6 haloalkyl;
  • C 3 -C 6 cycloalkyl optionally substituted with one or more substituent independently selected from halogen, amino, hydroxyl, -0-, Ci-C 6 haloalkyl, carboxyl, Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonyl, Ci-C 6 alkylcarbonylamino and a 3- to 6-membered saturated or unsaturated ring, optionally comprising one or more heteroatom selected from nitrogen, oxygen and sulphur, and optionally further comprising a bridging group, the ring being optionally substituted with one or more substituent independently selected from halogen, hydroxyl, -0-, Ci-C 6 alkyl, Ci-C 6 hydroxyalkyl and Ci-C 6 haloalkyl; (iv) Ci-C 6 alkylsulphonyl; or
  • R 7 and R 8 together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocyclic ring that optionally further comprises a ring nitrogen, oxygen or sulphur atom and that is optionally fused to a benzene ring to form a 8- to 11- membered ring system, the heterocyclic ring or ring system being optionally substituted with one or more substituent independently selected from halogen, hydroxyl, CONH 2 , Ci-C 6 alkyl, Ci-C 6 hydroxyalkyl, Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonyl, Ci-C 6 haloalkyl, Ci- C 6 alkylamino, Ci-C 6 alkylcarbonyl, Ci-C 6 alkylcarbonylamino and Ci-C 6 alkylaminocarbonyl; and
  • R 9 is hydrogen or Ci-C 6 alkyl; or a pharmaceutically acceptable salt thereof.
  • Another embodiment of the invention relates to compounds of formula I wherein: m is O or 1 ;
  • R 1 is halogen or Ci-C ⁇ haloalkyl;
  • Q is -CH 2 - or -C(O)-;
  • X, Y and Z are a bond, -CH 2 - or -C(O)-, provided that X, Y and Z are not all the same and that at least one of X, Y or Z is -C(O)-;
  • q is 1 or 2;
  • R 2 is hydrogen or C1-C4 alkyl
  • A is a bond, -O- or C1-C3 alkyl
  • R 3 is hydrogen, -NHC(O)R 6 , -C(O)NR 7 R 8 or Ci-C 3 alkyl optionally substituted by t substituents independently selected from halogen, cyano, amino or hydroxyl; t is O, 1 or 2;
  • R 4 is hydrogen, halogen, hydroxyl or Ci-C4alkoxy; p is O, 1 or 2;
  • R 5 is halogen, cyano, C 1 -C 3 alkoxy or Ci-C 3 haloalkyl
  • R 6 is (i) hydrogen or (ii) Ci-C 4 alkyl
  • R 7 and R 8 each independently represent; (i) hydrogen
  • C 3 -C 6 cycloalkyl optionally substituted with one or more substituent independently selected from halogen, amino, hydroxyl, -0-, Ci-C 6 haloalkyl, carboxyl, Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonyl and Ci-C 6 alkylcarbonylamino; or
  • R 7 and R 8 together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocyclic ring; or a pharmaceutically acceptable salt thereof.
  • a further embodiment of the invention relates to compounds of formula I wherein: wherein m is O or 1 ;
  • R 1 is halogen
  • Q is -CH 2 - or -C(O)- ;
  • X, Y and Z are a bond, -CH 2 - or -C(O)-, provided that X, Y and Z are not all the same and that at least one of X, Y or Z is -C(O)-; q is 1 or 2;
  • R 2 is hydrogen
  • A is a bond
  • R 3 is hydrogen, -NHC(O)R 6 or -C(O)NR 7 R 8 ;
  • R 4 is hydrogen, halogen, hydroxyl or Ci -C 3 alkoxy; p is 0 or 1 ;
  • R 5 is halogen or cyano
  • R 6 is (i) hydrogen or (ii) Ci-C 6 alkyl
  • R 7 and R 8 each independently represent; (i) hydrogen; (iii) C 3 -C 6 cycloalkyl; or
  • R 7 and R 8 together with the nitrogen atom to which they are attached form a 5- to 6- membered saturated heterocyclic ring; and or a pharmaceutically acceptable salt thereof.
  • m is 1 and R 1 is halogen, particularly a chlorine atom or a fluorine atom. In another embodiment R 1 is para-substituted on position 4.
  • Q is -CH 2 -. In another embodiment of the invention Q is -C(O)-.
  • X is bond
  • Y is CH 2 and Z is C(O).
  • X and Y are CH 2 and Z is C(O).
  • X is C(O) and Y and Z are CH 2 .
  • X and Y are a bond and Z is -C(O).
  • the integer q is 1. In another embodiment q is 2.
  • R 4 is hydrogen, halogen, hydroxyl, Ci-C ⁇ alkoxy or Ci-C 6 hydroxyalkyl, optionally substituted with halogen, cyano, hydroxyl, carboxyl or amido.
  • R 4 is hydrogen.
  • R 4 is halogen such as fluorine.
  • R 4 is hydroxyl.
  • R 4 is C 1 -C 4 alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy).
  • R 4 is methoxy.
  • A is a bond and R 3 is -NHC(O)R 6 or - C(O)NR 7 R 8 .
  • R 6 is selected from hydrogen.
  • R 6 is a C1-C4 alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl). In a particular embodiment of the present invention R 6 is methyl.
  • R 7 and R 8 independently present a hydrogen, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or R 7 and R 8 together with the nitrogen atom to which they are attached form a 5- to 6-membered heterocyclic ring.
  • R 7 is hydrogen and R 8 is cyclopropyl.
  • R 7 and R 8 form a pyrrolidine together with the nitrogen atom to which they are attached.
  • the integer p is 0, 1 or 2. In one embodiment p is 0. In yet another embodiment p is 1.
  • p is 1 and R 5 is a halogen, such as chlorine and fluorine. In another embodiment of the present invention p is 1 and R 5 is cyano.
  • alkyl includes both straight and branched chain alkyl groups and may be, but are not limited to methyl, ethyl, n-propyl, i- propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, neo-pentyl, n-hexyl or i-hexyl.
  • alkoxy and hydroxyalkyl refers to radicals of the general formula -O-R, wherein R is selected from a hydrocarbon radical.
  • alkoxy may include, but is not limited to methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy or propargyloxy.
  • 'hydroxyalkyl' may also include alkyl groups as defined above substituted by one or more hydroxyl groups.
  • cycloalkyl refers to an optionally substituted, partially or completely saturated monocyclic, bicyclic or bridged hydrocarbon ring system.
  • the term “Ci-C 6 cycloalkyl” may be, but is not limited to cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • the term "3- to 6-membered saturated or unsaturated ring' or '4- to 7-membered saturated or unsaturated heterocyclic ring' or '8- to 11-membered ring system', optionally comprising one or more heteroatom selected from nitrogen, oxygen and sulphur refers to a ringsystem having, in addition to carbon atoms, zero to three heteroatoms, including the oxidized form of nitrogen and sulfur and any quaternized form of a basic nitrogen, including, but not limited to cyclopropane, oxirane, cyclobutane, azetidine, cyclopentane, cyclohexane, benzyl, furane, thiophene, pyrrolidine, morpholine, piperidine, piperazine, pyrazine, azepane.
  • bicyclic ring refers to a ringsystem in which one (carbo)cycle is fused to another (carbo)cycle.
  • ringsystem refers to a hydrocarbon moiety comprising one to three fused rings, optionally having 6, 10 or 14 ⁇ atoms shared in a cyclic array and having, in addition to carbon atoms, zero to five heteroatoms.
  • Fused ringsystems may include, but are not limited to, 8- azabicyclo[3.2.1]octane, 3-azabicyclo[3.2.1]octane, 2-azabicyclo[2.2.2]octane, indole, indoline, benzofuran, benzothiophene, naphtalene, chroman, quinazoline, phenoxazine, azulene, adamantane, anthracene or phenoxazine.
  • haloalkyl means an alkyl group as defined above, which is substituted with halogen as defined above.
  • C 1 - Cehaloalkyl may include, but is not limited to fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl or bromopropyl
  • the compound of formula I is selected from ⁇ /-(2- ⁇ 3-[3-(4-chlorobenzyl)-2-oxoimidazolidin-l-yl]-2- hydroxypropoxy ⁇ phenyl)acetamide, or a pharmaceutically acceptable salt thereof.
  • the present invention relates to any one of the specific compounds mentioned above.
  • the compounds of formula I are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses the use of all geometric and optical isomers of the compounds of formula I and mixtures thereof including racemates. The use of tautomers and mixtures thereof also form an aspect of the present invention. Thus, compounds of formula I or relevant intermediates can be prepared as an enantiomeric mixture of the R and S enantiomers and optionally separated to provide both the R and S compounds.
  • the compounds of formula I may be used in the form of a pharmaceutically acceptable salt, solvates or solvated salts thereof, conceivably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, sulfphate, acetate, ascorbate, benzoate, 2- fluorobenzoate, 2,6-difluorobenzoate, (hemi)fumarate, furoate, succinate, maleate, tartrate, citrate, oxalate, xinafoate, methanesulphonate or/?-toluenesulphonate.
  • an acid addition salt such as a hydrochloride, hydrobromide, phosphate, sulfphate, acetate, ascorbate, benzoate, 2- fluorobenzoate, 2,6-difluorobenzoate, (hemi)fumarate, furoate, succinate, maleate, tartrate, citrate, oxalate, xinafo
  • Pharmaceutically acceptable salts may also be formed together with metals such as calcium, magnesium, sodium, potassium or zinc or bases such as piperazine, 2-aminoethanol, choline, diethylamine or diethanol amine.
  • the compounds of formula I may be used in the form of a pharmaceutically acceptable salt, solvates or solvated salts thereof, like an amino acid addition salt such as L-lysine, glycine, L-glutamine, L-asparagine or L- arganine.
  • a pharmaceutically acceptable salt also includes internal salt (zwitterionic) forms. Any reference to compounds of formula I or salts thereof also encompasses solvates of such compounds and solvates of such salts (e.g. hydrates).
  • the present invention further provides a process for the preparation of a compound of formula I or a pharmaceutically acceptable salt thereof as defined above which comprises: (a) reacting a compound of formula II
  • R 2 is as defined in formula I, and L 2 is a leaving group, such as halogen, in the presence of a suitable base;
  • A, R , R and R and integer p are as defined in formula I, or a protected derivative thereof, in the presence of a suitable base; or (d) reacting a compound of formula VIII wherein R is as defined in formula I, L 3 is a suitable leaving group like a halogen or an alkyl/aryl sulfonate with a compound of formula VII
  • R 2 , R 3 , R 4 and R 5 and integers p and q are as defined in formula I, with a compound of formula III; wherein, R 1 and Q and integer m are as defined in formula I, and L 1 is a suitable leaving group, like a halogen, in the presence of a suitable base,
  • Process (a) - (e) may conveniently be carried out in a suitable solvent, e.g. water or an organic solvent selected from alcohol (e.g. methanol or ethanol), a hydrocarbon (e.g. toluene), cyanides (e.g. acetonitrile or butyronitrile), ethers (THF, dioxane), NMP, DCM or DMF at a temperature of, for example 20 0 C or above, such as a temperature in the range from 25-150 0 C.
  • a suitable phase transfer catalyst such as tetrabutylammonium hydrosulfate or tetrabutylammonium iodide.
  • a suitable base In processes (a), (b), (c) and (d), the choice of a suitable base would be routine for a person skilled in the art, and would include both organic bases, such as trietylamine, DIPEA and KHMDS and inorganic bases, such as potassium or cesium carbonate and sodium hydroxide.
  • organic bases such as trietylamine, DIPEA and KHMDS
  • inorganic bases such as potassium or cesium carbonate and sodium hydroxide.
  • the active ingredients of the present invention may be administered by oral or parenteral (e.g. intravenous, subcutaneous, intramuscular or intraarticular) administration using conventional systemic dosage forms, such as tablets, capsules, pills, powders, aqueous or oily solutions or suspensions, emulsions and sterile injectable aqueous or oily solutions or suspensions.
  • the active ingredients may also be administered topically (e.g. to the lung and/or airways) in the form of solutions, suspensions, aerosols and dry powder formulations.
  • These dosage forms will usually include one or more pharmaceutically acceptable ingredients which may be selected, for example, from adjuvants, carriers, binders, lubricants, diluents, stabilising agents, buffering agents, emulsifying agents, viscosity-regulating agents, surfactants, preservatives, flavourings and colorants.
  • pharmaceutically acceptable ingredients which may be selected, for example, from adjuvants, carriers, binders, lubricants, diluents, stabilising agents, buffering agents, emulsifying agents, viscosity-regulating agents, surfactants, preservatives, flavourings and colorants.
  • the most appropriate method of administering the active ingredients is dependent on a number of factors.
  • a pharmaceutical composition comprising a compound of formula I or (Ia), or pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable adjuvant, diluent or carrier.
  • compositions of the present invention may be prepared by mixing the active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier. Therefore, in a further aspect of the present invention there is provided a process for the preparation of a pharmaceutical composition, which comprises mixing a compound of formula I or (Ia), or pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the active ingredient of the present invention is administered by inhalation.
  • the active ingredient is conveniently administered via inhalation (e.g. topically to the lung and/or airways) in the form of solutions, suspensions, aerosols or dry powder formulations. Administration may be by inhalation orally or intranasally.
  • the active ingredient is preferably adapted to be administered, from a dry powder inhaler, pressurised metered dose inhaler, or a nebuliser.
  • the active ingredient may be used in admixture with one or more pharmaceutically acceptable additives, diluents or carriers.
  • suitable diluents or carriers include lactose (e.g. the monohydrate), dextran, mannitol or glucose.
  • Metered dose inhaler devices may be used to administer the active ingredients, dispersed in a suitable propellant and with or without additional excipients such as ethanol, a surfactant, a lubricant, an anti-oxidant or a stabilising agent.
  • suitable propellants include hydrocarbon, chlorofiuorocarbon and hydrofiuoroalkane (e.g. heptafiuoroalkane) propellants, or mixtures of any such propellants.
  • Preferred propellants are P 134a and P227, each of which may be used alone or in combination with other propellants and/or surfactant and/or other excipients.
  • Nebulised aqueous suspensions, solutions may also be employed, with or without a suitable pH and/or tonicity adjustment, either as a unit-dose or multi-dose formulations.
  • Dry powder inhalers may be used to administer the active ingredients, alone or in combination with a pharmaceutically acceptable carrier, in the later case either as a finely divided powder or as an ordered mixture.
  • the dry powder inhaler may be single dose or multi-dose and may utilise a dry powder or a powder-containing capsule.
  • the active ingredient When the active ingredient is adapted to be administered, via a nebuliser it may be in the form of a nebulised aqueous suspension or solution, with or without a suitable pH or tonicity adjustment, either as a single dose or multidose device.
  • Metered dose inhaler, nebuliser and dry powder inhaler devices are well known and a variety of such devices are available.
  • the present invention provides a pharmaceutical product comprising, an active ingredient which is a compound of formula I or (Ia), or a pharmaceutically acceptable salt thereof, formulated for inhaled administration.
  • the compound of formula I or (Ia), or a pharmaceutically acceptable salt thereof may be administered orally.
  • the compounds of formula I or (Ia), salts and solvates thereof have activity as pharmaceuticals, and are surprisingly potent modulators of chemokine receptor (especially CCRl receptor) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative and hyperproliferative diseases and immunologically-mediated diseases.
  • chemokine receptor especially CCRl receptor
  • a compound of the invention can be used in the treatment of:
  • a compound of the invention can be used in the treatment of:
  • respiratory tract obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature
  • osteoarthritides associated with or including osteoarthritis/osteoarthrosis both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and low back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondarthropathy; septic arthritis and other infection- related arthopathies and bone disorders such as tuberculosis, including Potts' disease and Poncet's syndrome; acute and chronic crystal-induced synovitis including urate gout, calcium pyrophosphate deposition disease, and calcium apatite related tendon, bursal and synovial inflammation; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed connective tissue
  • musculoskeletal disorders due to injury [for example sports injury] or disease: arthitides (for example rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy), other joint disease (such as intervertebral disc degeneration or temporomandibular joint degeneration), bone remodelling disease (such as osteoporosis, Paget's disease or osteonecrosis), polychondritits, scleroderma, mixed connective tissue disorder, spondyloarthropathies or periodontal disease (such as periodontitis);
  • arthitides for example rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy
  • other joint disease such as intervertebral disc degeneration or temporomandibular joint degeneration
  • bone remodelling disease such as osteoporosis, Paget's disease or osteonecrosis
  • polychondritits scleroderma
  • mixed connective tissue disorder spondylo
  • skin psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis;cutaneous lymphomas, non-melanoma
  • eyes blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; ulceris; anterior and posterior uveitis; choroiditis; autoimmune; degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral , fungal, and bacterial;
  • gastrointestinal tract glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; coeliac disease, irritable bowel syndrome, and food-related allergies which may have effects remote from the gut (for example migraine, rhinitis or eczema);
  • abdominal hepatitis, including autoimmune, alcoholic and viral; fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic;
  • nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvovaginitis; Peyronie's disease; erectile dysfunction (both male and female); 9. allograft rejection: acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or chronic graft versus host disease;
  • CNS Alzheimer's disease and other dementing disorders including CJD and nvCJD; amyloidosis; multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; acute and chronic pain (acute, intermittent or persistent, whether of central or peripheral origin) including visceral pain, headache, migraine, trigeminal neuralgia, atypical facial pain, joint and bone pain, pain arising from cancer and tumor invasion, neuropathic pain syndromes including diabetic, post-herpetic, and HIV-associated neuropathies; neurosarcoidosis; central and peripheral nervous system complications of malignant, infectious or autoimmune processes;
  • cardiovascular atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis , inflammatory and auto-immune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infective (for example syphilitic); vasculitides; disorders of the proximal and peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins;
  • oncology treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes; and,
  • gastrointestinal tract Coeliac disease, proctitis, eosinopilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, microscopic colitis, indeterminant colitis, irritable bowel disorder, irritable bowel syndrome, non-inflammatory diarrhea, food- related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema.
  • the invention further relates to combination therapies wherein a compound of the invention, or a pharmaceutical composition or composition comprising a compound of the invention, is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed.
  • NSAIDs non-steroidal anti-inflammatory agents
  • COX-I / COX-2 inhibitors whether applied topically or systemically
  • piroxicam diclofenac
  • propionic acids such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen
  • fenamates such as mefenamic acid, indomethacin, sulindac, azapropazone, pyrazolones such as phenylbutazone, salicylates such as aspirin
  • selective COX-2 inhibitors such as
  • the present invention still further relates to the combination of a compound of the invention, together with a cytokine or agonist or antagonist of cytokine function, (including agents which act on cytokine signalling pathways such as modulators of the SOCS system) including alpha-, beta-, and gamma- interferons; insulin-like growth factor type I (IGF-I); interleukins (IL) including ILl to 17, and interleukin antagonists or inhibitors such as anakinra; tumour necrosis factor alpha (TNF- ⁇ ) inhibitors such as anti-TNF monoclonal antibodies (for example infliximab; adalimumab, and CDP-870) and TNF receptor antagonists including immunoglobulin molecules (such as etanercept) and low-molecular- weight agents such as pentoxyfylline.
  • a cytokine or agonist or antagonist of cytokine function including agents which act on cytokine signalling pathways such as modulators of the SO
  • the invention relates to a combination of a compound of the invention, with a monoclonal antibody targeting B-Lymphocytes (such as CD20 (rituximab), MRA-aIL16R and T-Lymphocytes, CTLA4-Ig, HuMax 11-15).
  • B-Lymphocytes such as CD20 (rituximab), MRA-aIL16R and T-Lymphocytes, CTLA4-Ig, HuMax 11-15.
  • the present invention still further relates to the combination of a compound of the invention, with a modulator of chemokine receptor function such as an antagonist of CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO and CCRl 1 (for the C-C family); CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C- X-C family) and CX 3 CRl for the C-X 3 -C family.
  • a modulator of chemokine receptor function such as an antagonist of CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO and CCRl 1 (for the C-C family); CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C- X-C family) and CX 3 CRl for the C-
  • the present invention further relates to the combination of a compound of the invention, with an inhibitor of matrix metalloprotease (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP- 1), collagenase-2 (MMP-8), collagenase-3 (MMP- 13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-IO), and stromelysin-3 (MMP-11) and MMP-9 and MMP- 12, including agents such as doxycycline.
  • MMPs matrix metalloprotease
  • the present invention still further relates to the combination of a compound of the invention, and a leukotriene biosynthesis inhibitor, 5 -lipoxygenase (5-LO) inhibitor or 5- lipoxygenase activating protein (FLAP) antagonist such as; zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; a N-(5-substituted)-thiophene-2- alkylsulfonamide; 2,6-di-tert-butylphenolhydrazones; a methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; a pyridinyl-substituted 2-cyanonaphthalene compound such as L-739,010; a 2-cyanoquinoline compound such as L-746,530; or an indole or quinoline compound such as MK-591, MK-886, and BAY x 1005.
  • the present invention further relates to the combination of a compound of the invention, and a receptor antagonist for leukotrienes (LT) B4, LTC4, LTD4, and LTE4.
  • a receptor antagonist for leukotrienes (LT) B4, LTC4, LTD4, and LTE4 selected from the group consisting of the phenothiazin-3-ls such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.
  • a receptor antagonist for leukotrienes (LT) B4, LTC4, LTD4, and LTE4 selected from the
  • the present invention still further relates to the combination of a compound of the invention, and a phosphodiesterase (PDE) inhibitor such as a methylxanthanine including theophylline and aminophylline; a selective PDE isoenzyme inhibitor including a PDE4 inhibitor an inhibitor of the isoform PDE4D, or an inhibitor of PDE5.
  • PDE phosphodiesterase
  • the present invention still further relates to the combination of a compound of the invention, and an endothelin antagonist such as Tezosentan, Bosentan, Enrasentan, and Sixtasentan.
  • an endothelin antagonist such as Tezosentan, Bosentan, Enrasentan, and Sixtasentan.
  • the present invention still further relates to the combination of a compound of the invention, and an angiotensin II antagonist such as Azilzartan, Losartan, Valsartan, Candesartan, and Telmisartan.
  • an angiotensin II antagonist such as Azilzartan, Losartan, Valsartan, Candesartan, and Telmisartan.
  • the present invention still further relates to the combination of a compound of the invention, or a pharmacuetically acceptable salt thereof, and a dual antagonists for both angiotensin II and endothelin A receptors (DARAs) such as disclosed in WO2000001389 and WO2001044239.
  • DARAs angiotensin II and endothelin A receptors
  • the present invention further relates to the combination of a compound of the invention, and an adenosine A2a agonist such as CGS-21680 and/or an adenosine A3 agonist such as IB-MECA and/or an adenosine A2b antagonist.
  • an adenosine A2a agonist such as CGS-21680 and/or an adenosine A3 agonist such as IB-MECA and/or an adenosine A2b antagonist.
  • the present invention further relates to the combination of a compound of the invention, and a histamine type 1 receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, or mizolastine; applied orally, topically or parenterally.
  • a histamine type 1 receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, or mizolastine
  • the present invention still further relates to the combination of a compound of the invention, and a proton pump inhibitor (such as omeprazole) or a gastroprotective histamine type 2 receptor antagonist.
  • a proton pump inhibitor such as omeprazole
  • a gastroprotective histamine type 2 receptor antagonist such as a gastroprotective histamine type 2 receptor antagonist.
  • the present invention further relates to the combination of a compound of the invention, and an antagonist of the histamine type 4 receptor.
  • the present invention still further relates to the combination of a compound of the invention, and an alpha- l/alpha-2 adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, tramazoline hydrochloride or ethylnorepinephrine hydrochloride.
  • an alpha- l/alpha-2 adrenoceptor agonist vasoconstrictor sympathomimetic agent such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydroch
  • the present invention further relates to the combination of a compound of the invention, and an anticholinergic agents including muscarinic receptor (Ml, M2, and M3) antagonist such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine.
  • Ml, M2, and M3 antagonist such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine.
  • the present invention still further relates to the combination of a compound of the invention, and a beta-adrenoceptor agonist (including beta receptor subtypes 1-4) such as isoprenaline, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, or pirbuterol, or a chiral enantiomer thereof.
  • a beta-adrenoceptor agonist including beta receptor subtypes 1-4
  • beta receptor subtypes 1-4 such as isoprenaline, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, or pirbuterol, or a chiral enantiomer thereof.
  • the present invention further relates to the combination of a compound of the invention, and a chromone, such as sodium cromoglycate or nedocromil sodium.
  • a chromone such as sodium cromoglycate or nedocromil sodium.
  • the present invention still further relates to the combination of a compound of the invention, with a glucocorticoid, such as flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate.
  • a glucocorticoid such as flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate.
  • the present invention further relates to the combination of a compound of the invention, with an agent that modulates a nuclear hormone receptor such as PPARs.
  • the present invention still further relates to the combination of a compound of the invention, together with an immunoglobulin (Ig) or Ig preparation or an antagonist or antibody modulating Ig function such as anti-IgE (for example omalizumab).
  • Ig immunoglobulin
  • Ig preparation or an antagonist or antibody modulating Ig function
  • anti-IgE for example omalizumab
  • the present invention further relates to the combination of a compound of the invention, and another systemic or topically-applied anti-inflammatory agent, such as thalidomide or a derivative thereof, a retinoid, dithranol or calcipotriol.
  • a compound of the invention and another systemic or topically-applied anti-inflammatory agent, such as thalidomide or a derivative thereof, a retinoid, dithranol or calcipotriol.
  • the present invention still further relates to the combination of a compound of the invention, and combinations of aminosalicylates and sulfapyridine such as sulfasalazine, mesalazine, balsalazide, and olsalazine; and immunomodulatory agents such as the thiopurines, and corticosteroids such as budesonide.
  • aminosalicylates and sulfapyridine such as sulfasalazine, mesalazine, balsalazide, and olsalazine
  • immunomodulatory agents such as the thiopurines, and corticosteroids such as budesonide.
  • the present invention further relates to the combination of a compound of the invention, together with an antibacterial agent such as a penicillin derivative, a tetracycline, a macrolide, a beta-lactam, a fluoroquinolone, metronidazole, an inhaled aminoglycoside; an antiviral agent including acyclovir, famciclovir, valaciclovir, ganciclovir, cidofovir, amantadine, rimantadine, ribavirin, zanamavir and oseltamavir; a protease inhibitor such as indinavir, nelfinavir, ritonavir, and saquinavir; a nucleoside reverse transcriptase inhibitor such as didanosine, lamivudine, stavudine, zalcitabine or zidovudine; or a non-nucleoside reverse transcriptase inhibitor such as nevirap
  • the present invention still further relates to the combination of a compound of the invention, and a cardiovascular agent such as a calcium channel blocker, a beta- adrenoceptor blocker, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-2 receptor antagonist; a lipid lowering agent such as a statin or a fibrate; a modulator of blood cell morphology such as pentoxyfylline; thrombolytic, or an anticoagulant such as a platelet aggregation inhibitor.
  • a cardiovascular agent such as a calcium channel blocker, a beta- adrenoceptor blocker, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-2 receptor antagonist
  • ACE angiotensin-converting enzyme
  • angiotensin-2 receptor antagonist angiotensin-2 receptor antagonist
  • a lipid lowering agent such as a statin or a fibrate
  • a modulator of blood cell morphology such as pentoxyfylline
  • the present invention further relates to the combination of a compound of the invention, and a CNS agent such as an antidepressant (such as sertraline), an anti-Parkinsonian drug (such as deprenyl, L-dopa, ropinirole, pramipexole, a MAOB inhibitor such as selegine and rasagiline, a comP inhibitor such as tasmar, an A-2 inhibitor, a dopamine reuptake inhibitor, an NMDA antagonist, a nicotine agonist, a dopamine agonist or an inhibitor of neuronal nitric oxide synthase), or an anti- Alzheimer's drug such as donepezil, rivastigmine, tacrine, a COX-2 inhibitor, propentofylline or metrifonate.
  • a CNS agent such as an antidepressant (such as sertraline), an anti-Parkinsonian drug (such as deprenyl, L-dopa, ropinirole,
  • the present invention still further relates to the combination of a compound of the invention, and an agent for the treatment of acute or chronic pain, such as a centrally or peripherally-acting analgesic (for example an opioid or derivative thereof), carbamazepine, phenytoin, sodium valproate, amitryptiline or other anti-depressant agent-s, paracetamol, or a non-steroidal anti-inflammatory agent.
  • analgesic for example an opioid or derivative thereof
  • carbamazepine for example an opioid or derivative thereof
  • phenytoin for example an opioid or derivative thereof
  • sodium valproate for example an opioid or derivative thereof
  • amitryptiline or other anti-depressant agent-s for example an opioid or derivative thereof
  • paracetamol for example an opioid or derivative thereof
  • non-steroidal anti-inflammatory agent for example an opioid or derivative thereof
  • the present invention further relates to the combination of a compound of the invention, together with a parenterally or topically-applied (including inhaled) local anaesthetic agent such as lignocaine or a derivative thereof.
  • a parenterally or topically-applied (including inhaled) local anaesthetic agent such as lignocaine or a derivative thereof.
  • a compound of the present invention can also be used in combination with an anti- osteoporosis agent including a hormonal agent such as raloxifene, or a biphosphonate such as alendronate.
  • a hormonal agent such as raloxifene
  • a biphosphonate such as alendronate.
  • the present invention still further relates to the combination of a compound of the invention, together with a: (i) tryptase inhibitor; (ii) platelet activating factor (PAF) antagonist; (iii) interleukin converting enzyme (ICE) inhibitor; (iv) IMPDH inhibitor; (v) adhesion molecule inhibitors including VLA-4 antagonist; (vi) cathepsin; (vii) kinase inhibitor such as an inhibitor of tyrosine kinase (such as Btk, Itk, Jak3 or MAP, for example Gefitinib or Imatinib mesylate), a serine / threonine kinase (such as an inhibitor of a MAP kinase such as p38, JNK, protein kinase A, B or C, or inhibitors of kappaB kinases, such as IKKl, IKK2 or IKK3), or a kinase involved in cell cycle regulation (such
  • - or B.sub2. -receptor antagonist for example colchicine;
  • anti-gout agent for example colchicine;
  • xanthine oxidase inhibitor for example allopurinol;
  • uricosuric agent for example probenecid, sulfinpyrazone or benzbromarone;
  • growth hormone secretagogue for example transforming growth factor (TGF ⁇ );
  • PDGF platelet-derived growth factor
  • PDGF platelet-derived growth factor
  • fibroblast growth factor for example basic fibroblast growth factor (bFGF);
  • GM-CSF granulocyte macrophage colony stimulating factor
  • capsaicin cream for example tachykinin NK.
  • NKP-608C sub 1. or NK.sub3.
  • receptor antagonist such as NKP-608C, SB-233412 (talnetant) or D-4418;
  • elastase inhibitor such as UT-77 or ZD-0892;
  • TACE TNF-alpha converting enzyme inhibitor
  • iNOS induced nitric oxide synthase
  • chemoattractant receptor-homologous molecule expressed on TH2 cells such as a CRTH2 antagonist
  • inhibitor of P38 agent modulating the function of Toll-like receptors (TLR),
  • agent modulating the activity of purinergic receptors such as P2X7; or
  • inhibitor of transcription factor activation such as NFkB, API, or STATS.
  • a compound of the invention can also be used in combination with an existing therapeutic agent for the treatment of cancer, for example suitable agents include: (i) an antiproliferative/antineoplastic drug or a combination thereof, as used in medical oncology, such as an alkylating agent (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan or a nitrosourea); an antimetabolite (for example an antifolate such as a fluoropyrimidine like 5-fiuorouracil or tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine or paclitaxel); an antitumour antibiotic (for example an anthracycline such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C,
  • a cytostatic agent such as an antioestrogen (for example tamoxifen, toremifene, raloxifene, droloxifene or iodoxyfene), an oestrogen receptor down regulator (for example fulvestrant), an antiandrogen (for example bicalutamide, flutamide, nilutamide or cyproterone acetate), a LHRH antagonist or LHRH agonist (for example goserelin, leuprorelin or buserelin), a progestogen (for example megestrol acetate), an aromatase inhibitor (for example as anastrozole, letrozole, vorazole or exemestane) or an inhibitor of 5 ⁇ -reductase such as finasteride;
  • an antioestrogen for example tamoxifen, toremifene, raloxifene, droloxifene or iodoxyfene
  • an agent which inhibits cancer cell invasion for example a metalloproteinase inhibitor like marimastat or an inhibitor of urokinase plasminogen activator receptor function
  • an inhibitor of growth factor function for example: a growth factor antibody (for example the anti-erbb2 antibody trastuzumab, or the anti-erbbl antibody cetuximab [C225]), a farnesyl transferase inhibitor, a tyrosine kinase inhibitor or a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family (for example an EGFR family tyrosine kinase inhibitor such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3- morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD 1839), N-(3-ethynylphenyl)-6,7- bis
  • an antiangio genie agent such as one which inhibits the effects of vascular endothelial growth factor (for example the anti-vascular endothelial cell growth factor antibody bevacizumab, a compound disclosed in WO 97/22596, WO 97/30035, WO 97/32856 or WO 98/13354), or a compound that works by another mechanism (for example linomide, an inhibitor of integrin ⁇ v ⁇ 3 function or an angiostatin);
  • vascular endothelial growth factor for example the anti-vascular endothelial cell growth factor antibody bevacizumab, a compound disclosed in WO 97/22596, WO 97/30035, WO 97/32856 or WO 98/13354
  • a compound that works by another mechanism for example linomide, an inhibitor of integrin ⁇ v ⁇ 3 function or an angiostatin
  • vascular damaging agent such as combretastatin A4, or a compound disclosed in WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 or WO 02/08213;
  • an agent used in antisense therapy for example one directed to one of the targets listed above, such as ISIS 2503, an anti-ras antisense;
  • an agent used in a gene therapy approach for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; or (ix) an agent used in an immunotherapeutic approach, for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as trans fection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.
  • GDEPT gene-directed enzyme pro-drug
  • the compounds of the invention can be combined with one or more agents for the treatment of such a condition.
  • the one or more agents is selected from the list comprising: D a PDE4 inhibitor including an inhibitor of the isoform PDE4D; D a selective ⁇ .sub2.
  • adrenoceptor agonist such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, pirbuterol or indacaterol;
  • D a muscarinic receptor antagonist for example a Ml , M2 or M3 antagonist, such as a selective M3 antagonist
  • a Ml , M2 or M3 antagonist such as a selective M3 antagonist
  • D a steroid such as budesonide
  • D an inhibitor of p38 kinase function D an inhibitor of matrix metalloproteases, most preferably targeting MMP -2, -9 or MMP- 12; or,
  • D an inhibitor of neutrophil serine proteases, most preferably neutrophil elastase or proteinase 3.
  • the compounds of the invention can be administered by inhalation or by the oral route and the other agent can be administered by inhalation or by the oral route.
  • the compounds of the invention and the other agent may be administered together. They may be administered sequencially. Or they may be administered separately.
  • One embodiment of the present invention provides a compound of formula I or (Ia) or a pharmaceutically-acceptable salt, solvates or solvated salts, as hereinbefore defined for use in therapy.
  • Another embodiment of the present invention provides the use of a compound of formula I or (Ia) or a pharmaceutically-acceptable salt, solvates or solvated salts, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of CCRl activity is beneficial.
  • a further embodiment of the present invention provides the use of a compound of formula I or (Ia) or a pharmaceutically-acceptable salt, solvates or solvated salts, as hereinbefore defined in the manufacture of a medicament for treating a respiratory disease.
  • Yet another embodiment of the present invention provides the use of a compound of formula I or (Ia) or a pharmaceutically-acceptable salt, solvates or solvated salts, as hereinbefore defined in the manufacture of a medicament for treating an airways disease.
  • Yet a further embodiment of present invention provides the use of a compound of formula I or (Ia) or a pharmaceutically-acceptable salt, solvates or solvated salts, as hereinbefore defined in the manufacture of a medicament for treating an inflammatory disease.
  • One embodiment of the present invention provides the use of a compound of formula I or (Ia) or a pharmaceutically-acceptable salt, solvates or solvated salts, as hereinbefore defined in the manufacture of a medicament for treating chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Another embodiment of the present invention provides the use of a compound of formula I or (Ia) or a pharmaceutically-acceptable salt, solvates or solvated salts, as hereinbefore defined in the manufacture of a medicament for treating asthma.
  • a further embodiment of the present invention provides a method of treatment of respiratory diseases, airway diseases, inflammatory diseases, COPD and/or asthma, or any of the other disorders mentioned above, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula I or (Ia), or a pharmaceutically acceptable salt, solvates or solvated salts, as hereinbefore defined.
  • One embodiment of the invention relates to an agent for the treatment of respiratory diseases, airway diseases, inflammatory diseases, COPD and/or asthma, , or any of the other disorders mentioned above, which comprises as active ingredient a compound of formula I or (Ia) or a pharmaceutically-acceptable salt, solvates or solvated salts.
  • Another embodiment relates to the use of a pharmaceutical composition comprising the compound of formula I or (Ia) for the treatment of respiratory diseases, airway diseases, inflammatory diseases, COPD and/or asthma, or any of the other disorders mentioned above.
  • the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary.
  • the terms “therapeutic” and “therapeutically” should be construed accordingly.
  • inhibitor and “antagonist” mean a compound that by any means, partly or completely, blocks the transduction pathway leading to the production of a response by the agonist.
  • disorder means any condition and disease associated with CCRl receptor activity.
  • the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.
  • the daily dosage of the compound of formula I or (Ia) may be in the range from 0.001 mg/kg to 30 mg/kg.
  • the compound of formula I or (Ia) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula I or (Ia) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable djuvants, diluents and/or carriers.
  • the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
  • Solvent A 0.1 %TF A/water
  • Solvent B 0.08%TFA/acetonitrile Flow: 1 ml/min
  • Method B Instrument Agilent 1100; Column: XTerra C8, 100 x 3 mm, 5 ⁇ particle size,
  • step i using imidazolin-2-one (430 mg), 4-chlorobenzyl bromide (1.03 g) and potassium tert butoxide (560 mg) to give sub title compound (145 mg).
  • HEK293 cells from ECACC, stably expressing recombinant human CCRl (HEK-CCRl) were used to prepare cell membranes containing CCRl .
  • the membranes were stored at -70
  • cpm test average cpm in wells with membranes and compound and [ 125 I] MIP- l ⁇ ;
  • NSB average cpm in the wells with membranes and MIP-Ia and [ 125 I] MIP- l ⁇ (nonspecific binding);
  • BO average cpm in wells with membranes and assay buffer and [ 125 I] MIP-Ia (maximum binding).
  • the molar concentration of compound producing 50% displacement was derived using the Excel-based program XLfit (version 2.0.9) to fit data to a 4-parameter logistics function.
  • the compounds were found to have activity less then 1 ⁇ M.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés représentés par la formule (I) ou un sel pharmaceutiquement acceptable de ceux-ci, Q, X, Y, Z, A, R1, R2, R3, R4, R5, m, q et p étant tels que définis dans la revendication (1). L'invention concerne également des procédés de préparation de ces composés, des intermédiaires employés dans leur préparation, des compositions pharmaceutiques contenant ces composés et leur utilisation en thérapie.
PCT/SE2008/050520 2007-05-07 2008-05-07 Nouveaux dérivés de benzyl-2-oxo-pipérazinyl/7-oxo/5-oxa-[1,4]-diazépanyl/2-oxo- tétrahydropyrimidinyle WO2008136754A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91639007P 2007-05-07 2007-05-07
US60/916,390 2007-05-07

Publications (1)

Publication Number Publication Date
WO2008136754A1 true WO2008136754A1 (fr) 2008-11-13

Family

ID=39943761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2008/050520 WO2008136754A1 (fr) 2007-05-07 2008-05-07 Nouveaux dérivés de benzyl-2-oxo-pipérazinyl/7-oxo/5-oxa-[1,4]-diazépanyl/2-oxo- tétrahydropyrimidinyle

Country Status (1)

Country Link
WO (1) WO2008136754A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006938A1 (fr) 2008-07-16 2010-01-21 F. Hoffmann-La Roche Ag Nouveaux composés hétérocycliques pour le traitement d'une maladie cardiovasculaire
WO2010150281A2 (fr) 2009-06-26 2010-12-29 Panacea Biotec Ltd. Nouveaux azabicyclohexanes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062757A1 (fr) * 2000-02-25 2001-08-30 Astrazeneca Ab Nouveaux composes
WO2001098272A1 (fr) * 2000-06-20 2001-12-27 Astrazeneca Ab Nouveaux composés

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062757A1 (fr) * 2000-02-25 2001-08-30 Astrazeneca Ab Nouveaux composes
WO2001062728A1 (fr) * 2000-02-25 2001-08-30 Astrazeneca Ab Nouveaux composes
WO2001062729A1 (fr) * 2000-02-25 2001-08-30 Astrazeneca Ab Nouveaux composes
WO2001098272A1 (fr) * 2000-06-20 2001-12-27 Astrazeneca Ab Nouveaux composés

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006938A1 (fr) 2008-07-16 2010-01-21 F. Hoffmann-La Roche Ag Nouveaux composés hétérocycliques pour le traitement d'une maladie cardiovasculaire
US8071586B2 (en) 2008-07-16 2011-12-06 Hoffmann-La Roche Inc. Heterocyclyl compounds
WO2010150281A2 (fr) 2009-06-26 2010-12-29 Panacea Biotec Ltd. Nouveaux azabicyclohexanes

Similar Documents

Publication Publication Date Title
US8507544B2 (en) Bi-aryl amide compounds as CRTh2 receptor modulators
US7741360B2 (en) Bi-aryl or aryl-heteroaryl substituted indoles
US20080255150A1 (en) Novel Compounds
US8058294B2 (en) Pharmaceutical salts of N-[2-(diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-napthyl)ethoxy]propanamide
US20120232101A1 (en) Novel Compounds
WO2008104752A1 (fr) Dihydropytidones inhibiteurs d'élastase
WO2008121065A1 (fr) Nouveaux dérivés de pyrrolidine utilisés comme antagonistes du récepteur de chimiokines
US20080293742A1 (en) Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4
US20100081692A1 (en) Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma
US20080058309A1 (en) Novel Compounds 171
US20090042942A1 (en) Muscarinic Receptor Antagonists
US20080200505A1 (en) Piperidines for the Treatment of Chemokine Mediated Diseases
US20090118288A1 (en) N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor
AU2005257707B2 (en) Chemical compounds I
US20120289513A1 (en) (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
US20090012125A1 (en) Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them
WO2008136754A1 (fr) Nouveaux dérivés de benzyl-2-oxo-pipérazinyl/7-oxo/5-oxa-[1,4]-diazépanyl/2-oxo- tétrahydropyrimidinyle
WO2008121066A1 (fr) Nouvelles spiropipéridines ou spiropyrrolidines tricycliques et leur utilisation en tant que modulateurs des récepteurs de chimiokines
WO2008150231A1 (fr) Nouveaux composés hétérocycliques utilisés dans le traitement de troubles respiratoires, des voies aériennes, ou de troubles inflammatoires
WO2007035154A1 (fr) Nouveaux dérivés de n-pyrazinil-phénylsulfonamide en tant que modulateurs du récepteur de chimiokine pour le traitement de l'asthme
US20090197914A1 (en) Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them
HK1148002B (en) A quinoline derivative acting as a p2x7-receptor antagonist
HK1148002A1 (en) A quinoline derivative acting as a p2x7-receptor antagonist

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08794132

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08794132

Country of ref document: EP

Kind code of ref document: A1